Additionally, OX40/OX40L-targeting antibodies have been used in preclinical and clinical studies in a variety of conditions, such as allergy, autoimmunity and cancer9–11, which are pathological situations characterized by very different types of inflammatory contexts. Here, TNFRSF4 is linked to allergic disease.